Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
AuMake Ltd. ( (AU:AUK) ) has provided an update.
AuMake Limited has unveiled a revised strategy for FY26 and FY27 that centres on profitable growth in its core “Nutritionals” segment and an expanded over-the-counter medicine offering into China. The company plans to diversify into higher value nutritional products, launch six OTC online stores on major Chinese ecommerce platforms, and deepen brand partnerships while exploring adjacent health, wellness, personal care and FMCG categories.
Following a comprehensive business review, AuMake will streamline its structure by exiting two non-performing joint ventures and shifting all future operations into wholly owned subsidiaries. The company is also moving to an asset-light, virtual Australian office, cutting executive and head office costs by more than $500,000 annually, while consolidating board oversight roles and appointing a Head of China to strengthen control over its Hong Kong and Hangzhou operations.
The most recent analyst rating on (AU:AUK) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on AuMake Ltd. stock, see the AU:AUK Stock Forecast page.
More about AuMake Ltd.
AuMake Limited is an Australia-based company focused on the sales and marketing of global health-related brands into the China market. The business targets the nutritionals and over-the-counter medicine segments, leveraging ecommerce platforms, particularly key Chinese online marketplaces, and operates through Hong Kong and Hangzhou divisions to serve its established customer base.
Current Market Cap: A$11.54M
For detailed information about AUK stock, go to TipRanks’ Stock Analysis page.